文献速递妇科

宫颈癌阳性淋巴结影响不一:新FIGO分期的意义

The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system.
PubMed 文献 · Gynecol Oncol · 2019-11-16

基于美国国家癌症数据库2004–2015年17,173例宫颈癌患者,评估淋巴结转移对生存的影响。淋巴结转移与生存恶化相关,且影响程度随T分期不同,T1B期IIIC2疾病影响最大。

要点

  • 淋巴结转移与宫颈癌生存恶化相关,IIIC1的HR为1.36,IIIC2的HR为2.14(多因素分析)。
  • T1B期IIIC2疾病影响最显著,单因素分析HR为5.38。
  • T3期淋巴结转移影响较小,IIIC2的HR为1.7,IIIC1的HR为1.2。

核心结论

  • 淋巴结转移对宫颈癌预后有负面影响,其生存影响随T分期变化,T1B期IIIC2疾病影响最大。

研究设计与样本

  • 回顾性查询美国国家癌症数据库2004–2015年数据,纳入17,173例宫颈癌患者,排除FIGO IVB、非腺癌/鳞癌、淋巴结状态未知及生存时间未知者。

主要发现

  • 在17,173例合格患者中,淋巴结转移与生存恶化相关:单因素分析IIIC1的HR为2.0(p<0.001),IIIC2的HR为3.9(p<0.001);多因素分析IIIC1的HR为1.36(p<0.001),IIIC2的HR为2.14(p<0.001)。
  • 在T1B期,IIIC2的影响最显著(HR 5.38,p<0.001),而IIIC1的HR为1.5(p=0.001)。
  • 在T3期,淋巴结转移的影响明显较小:IIIC2的HR为1.7(p<0.001),IIIC1的HR为1.2(p=0.02)。
  • 在T1B期内,较小的T分期(IB1-2)中IIIC1的生存无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer changed from a clinical system to a clinical/pathologic/radiologic system with stages IIIC1 and IIIC2 indicating positive pelvic and para-aortic lymph nodes, respectively. We evaluated the National Cancer Database (NCDB) for the impact on survival of lymph node metastases (LNM). METHODS: The NCDB from 2004 to 2015 was queried for patients with cervical cancer, yielding 115,819 patients. Patients with FIGO IVB (22,569), non-adeno/squamous cell histologies (5,909), unknown nodal status (60,695), or unknown survival time (9,473) were excluded. Survival was compared using Cox proportional hazard model based on nodal status. Univariate (UVA) and multivariate analyses (MVA) were done for the overall cohort, followed by UVA by individual stage. RESULTS: In 17,173 eligible patients, LNM negatively affected survival (UVA IIIC1 Hazard Ratio [HR] 2.0, p < 0.001, IIIC2 HR 3.9, p < 0.001, MVA IIIC1 HR 1.36, p < 0.001, IIIC2 HR 2.14, p < 0.001). In T1B, the effect of IIIC2 was most pronounced (HR 5.38, p < 0.001 versus HR 1.5 p = 0.001 for IIIC1 disease). In T3, the effect of LNM was markedly less: (HR 1.7, p < 0.001 for IIIC2 versus HR 1.2 p = 0.02 for IIIC1). Within T1B, there was no difference in survival for IIIC1 for the smaller T stages (IB1-2). CONCLUSION: In this study, LNM negatively affects prognosis in cervical cancer. The impact on survival varies by T stage with the greatest effect seen in stage T1B with IIIC2 disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. McComas KN, Torgeson AM, Ager BJ, et al. The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol. 2019. PMID: 31744640. doi:10.1016/j.ygyno.2019.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。